నైరూప్య

Theoretical model basis of clinical guidelines for Ebola viral infection containment in Lagos, Nigeria

Kingsley E Abhulimen

Clinical guidelines and biological characteristics models in bio drug synthesis, vaccine production and decision support system (DSS) applied to Ebola virus infection containment and clinical testing algorithms in Lagos, Nigeria. Clinical solutions consensus guided by systematic reviews of evidence, data, World Health Organization (WHO) analysis of technical reports in literature and discussions with representative of the Ebola virus containment team in Lagos, Nigeria. The therapeutic method for the treatment of Ebola virus in human host involves the processes of manufacture of a Bio-antiviral drug agent and its clinical therapy delivery to specific patient cases for the generation of mutated cloned T-cells (mutated CD4+ T-cells or mutated CD4 T lymphocytes), produced within the patient's body, to fight the Ebola virus. The mutation delivered using the antiviral active agent encoded in the bio capsules. Mutations caused in stem cells, which, within the patient's marrow, grow into the mutated T-cells capable of destroying the Ebola virus through an immune genome creation DNA sequencing that uses the retroviral RNA cells as hosts' pods. In the clinical cases diagnosis. Patient 0 is observed to show the highest vaccine index (0.415396) within the first three days because of its higher immunity index (0.91551) compared to patient 1, patient 2 and patient 3 which have immunity and vaccine index of (0.271027, 0.262412), (0.02204, 0.507298) and (0.751984,0.108534). Patient 1 disease index increased to (0.736847) from (0.395947) while the vaccine index (0.262412) has increased to (0.8708) while. Patient 2 which have vaccine index reduced to (0.144319) from (0.507298), and Patient 3 increase to (0.291349) from (0.108534) within the first six to nine days. Patient 0 shows reduced disease load to (0.401072) after 18-21 days from a high